Safety of protease inhibitors and Arbidol for SARS-CoV-2 pneumonia in Zhejiang Province, China.

Yong-zheng Guo; Kai-jin XU; Yong-tao LI; Jia-dan FU; Min XU; Ling YU; Ji-fang Sheng; Biao Zhu

Return

Safety of protease inhibitors and Arbidol for SARS-CoV-2 pneumonia in Zhejiang Province, China.

Author: Yong-Zheng GUO ¹ ; Kai-Jin XU ¹ ; Yong-Tao LI ¹ ; Jia-Dan FU ¹ ; Min XU ¹ ; Ling YU ¹ ; Ji-Fang SHENG ¹ ; Biao ZHU ¹
Author Information

1. Department of Infectious Diseases, State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.
Publication Type:Journal Article
Keywords: SARS-CoV; Lopinavir; Darunavir; Pneumonia; Lipid metabolism
MeSH: Adult; COVID-19/drug therapy*; China; Darunavir; Drug Combinations; Female; Humans; Indoles/therapeutic use*; Lipid Metabolism; Lopinavir; Male; Middle Aged; Protease Inhibitors/therapeutic use*; Retrospective Studies; Ritonavir; SARS-CoV-2/genetics*
From: Journal of Zhejiang University. Science. B 2020;21(12):948-954
CountryChina
Language:English
Abstract: The aim of this study was to evaluate the safety of an antiviral regimen of protease inhibitors combined with Arbidol (umifenovir) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia patients. The genomic sequence of SARS-CoV-2 is highly homologous to that of SARS-CoV (Zhou et al., 2020). Previously published basic and clinical research on anti-SARS-CoV treatment found that lopinavir/ritonavir (LPV/r) could improve the prognosis of SARS patients (Chan et al., 2003; Chu et al., 2004). Darunavir (DRV) is another protease inhibitor that blocks the binding of SARS-CoV-2 to human angiotensin-converting enzyme 2 (Omotuyi et al., 2020). The broad-spectrum antiviral drug Arbidol (umifenovir) also shows in vitro anti-SARS-CoV activity (Khamitov et al., 2008).